Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients
Clinical Pharmacology & Therapeutics · 2025-05 · 117 (5) · 1303-1312
DOI: 10.1002/cpt.3546 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 10.01.2025. Verfasst von Weijie Kong und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking University Third Hospital, Beijing, China. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Cytochrome P-450 CYP3A, Kidney Failure, Chronic, Liver-Specific Organic Anion Transporter 1. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
OATP1B, P‐gp, BCRP, and CYP3A are the most contributing drug‐metabolizing enzymes or transporters (DMETs) for commonly prescribed medication. Their activities may change in end‐stage renal disease (ESRD) patients with large inter‐individual variabilities (IIVs), leading to altered substrate drug exposure and ultimately elevated safety risk. However, the changing extent and indictive influencing factors are not quantified so far. Here, a microdose cocktail regimen containing five sensitive substrate drugs (pitavastatin, dabigatran etexilate, rosuvastatin, midazolam, and atorvastatin) for these DMETs was administrated to Chinese healthy volunteers and ESRD patients. Drug pharmacokinetics profiles were determined, together with physiological, pharmacogenetic, and gut microbiome signature. Population pharmacokinetic and machine learning model were established to identify key influencing factors and quantify their contribution to drug exposure change. The exposure of pitavastatin, dabigatran, rosuvastatin, and atorvastatin increased to 1.8‐, 3.1‐, 1.1‐, and 1.3‐fold, respectively, whereas midazolam exposure decreased by 72% in ESRD patients. Notably, in addition to disease state, the relative abundance of genus Veillonella and Clostridium_XIVb were firstly identified as significant influencing factors for PTV and RSV apparent clearance, respectively, suggesting their indicative role for OATP and BCRP activity evaluation. Moreover, several genera were found to strongly associate with drug clearance and reduce unexplained IIVs. Accordingly, it was estimated that OATP1B and intestine P‐gp activity decreased by 35–75% and 29–44%, respectively, whereas BCRP and CYP3A4 activity may upregulate to some extent. Our study provides a quantitative and mechanistic understanding of individual DMET activity and could support precision medicine of substrate drugs in ESRD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Peking University Third Hospital, Beijing, China.
- Drug Clinical Trial Center, Peking University Third Hospital, Beijing, China.
- Institute of Medical Innovation, Peking University Third Hospital, Beijing, China.
ORCID-Profile: Hao Liang, Wen Tang, Dongyang Liu
Zitieren
APA
Kong, W., Pan, Y., Wu, Y., Hu, Y., Jiang, Z., Tian, X., Bi, S., Wang, S., Feng, F., Jin, Y., Li, J., Li, H., Wang, Y., Liang, H., Tang, W., & Liu, D. (2025). Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients. Clinical Pharmacology & Therapeutics, 117(5), 1303-1312. https://doi.org/10.1002/cpt.3546
Vancouver
Kong W, Pan Y, Wu Y, Hu Y, Jiang Z, Tian X, et al. Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients. Clinical Pharmacology & Therapeutics. 2025;117(5):1303-1312. doi:10.1002/cpt.3546
BibTeX
@article{Kong2025,
author = {Kong, Weijie and Pan, Yuejuan and Wu, Yujie and Hu, Yiyi and Jiang, Zhenbin and Tian, Xinkui and Bi, Shuhong and Wang, Song and Feng, Feifei and Jin, Yuyan and Li, Jiayu and Li, Haiyan and Wang, Yue and Liang, Hao and Tang, Wen and Liu, Dongyang},
title = {Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
volume = {117},
number = {5},
pages = {1303--1312},
doi = {10.1002/cpt.3546}
}
EUVIMED